SCHEMBL10220174

SCHEMBL10220174

O=C(O)Cc1cccc(OCCC2CCN(c3nc4ccc(C(F)(F)F)cc4s3)CC2)c1

nearest known ligand 0.79

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.79
PPARG P37231 16/20 0.79
PPARA Q07869 13/20 0.79
CYP2C9 P11712 1/20 0.55
CSNK1D P48730 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10220210 0.90 PPARD (0.81) PPARDPPARGPPARACYP2C9
SCHEMBL10219895 0.90 PPARD (0.65) PPARDPPARGPPARACYP2C9CSNK1D
SCHEMBL10220144 0.88 PPARD (1.00) PPARDPPARGPPARACYP2C9
SCHEMBL10271564 0.88 PPARD (0.62) PPARDPPARGPPARACYP2C9
SCHEMBL10220199 0.88 PPARD (0.81) PPARDPPARGPPARACYP2C9
SCHEMBL10220203 0.88 PPARD (0.81) PPARDPPARGPPARACYP2C9
SCHEMBL10220206 0.88 PPARD (0.80) PPARDPPARGPPARACYP2C9
SCHEMBL10220176 0.85 PPARD (0.82) PPARDPPARGPPARA
SCHEMBL10220177 0.85 PPARD (0.59) PPARDPPARGPPARACYP2C9CSNK1D
SCHEMBL10219894 0.84 PCSK9 (0.65) PPARDPPARGPPARACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-8097610-B2 Derivative having PPAR agonistic activity SHIONOGI & CO., LTD. (JP) 2012-01-17 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG PPARD 1/4885PPARG 3/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.